Chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) is associated with poorer health-related quality of life (HRQoL), significant disability, need for renal replacement therapy (dialysis) in end stage disease, and increased renal and CV-associated mortality. Unfortunately, this disease is often silent until late stage, displaying few early symptoms, and as a result, only about 10% of patients with mild or moderate disease even know that they have CKD. Literature shows that about 40% of patients with T2DM will go on to develop CKD. As the burden of diabetes-associated CVD, renal, and other complications have become more widely acknowledged, it has become clear that pharmacists are an untapped resource to make patients aware of guideline-recommended screenings that can detect CKD early, provide and make recommendations to providers to optimize drug therapy, and counsel patients. It is imperative that pharmacists remain up-to-date on current and emerging treatments that may delay CKD progression and reduce the risk of CV events.
In this CMEO BriefCase, expert faculty will utilize a patient case to show the pathophysiological features of CKD and assess new efficacy and safety data for current and emerging therapies for CKD in patients with T2DM with a goal of improving co-management strategies.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Patel reports that he is on the speakers bureau for Abbott; Amarin Corporation; AstraZeneca; Bayer; Boehringer Ingelheim; Dexcom, Inc.; Lilly; Novo Nordisk; Xeris Pharmaceuticals, Inc.; and Zealand Pharma.
Dr. Busch reports that he receives research support from Afimmune; Amarin Corporation; Bayer; Lilly; Kowa Pharmaceuticals America, Inc.; and Novo Nordisk. He reports that he is on the speakers bureau for Amgen Inc.; AstraZeneca; Bayer; Lilly; and Novo Nordisk.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report:
CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).